DK333385A - Prostaglandinanaloge, fremgangsmaader til fremstilling heraf samt pharmaceutiske midler med indhold heraf - Google Patents

Prostaglandinanaloge, fremgangsmaader til fremstilling heraf samt pharmaceutiske midler med indhold heraf Download PDF

Info

Publication number
DK333385A
DK333385A DK333385A DK333385A DK333385A DK 333385 A DK333385 A DK 333385A DK 333385 A DK333385 A DK 333385A DK 333385 A DK333385 A DK 333385A DK 333385 A DK333385 A DK 333385A
Authority
DK
Denmark
Prior art keywords
sub
pgl
inalogue
prostagland
procedures
Prior art date
Application number
DK333385A
Other languages
English (en)
Other versions
DK333385D0 (da
Inventor
Katsuhiro Imaki
Hajimu Miyake
Tadao Okegawa
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of DK333385D0 publication Critical patent/DK333385D0/da
Publication of DK333385A publication Critical patent/DK333385A/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C07D307/935—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
    • C07D307/937—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans with hydrocarbon or substituted hydrocarbon radicals directly attached in position 2, e.g. prostacyclins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/005—Analogues or derivatives having the five membered ring replaced by other rings
    • C07C405/0075—Analogues or derivatives having the five membered ring replaced by other rings having the side-chains or their analogues or derivatives attached to a condensed ring system
    • C07C405/0083—Analogues or derivatives having the five membered ring replaced by other rings having the side-chains or their analogues or derivatives attached to a condensed ring system which is only ortho or peri condensed, e.g. carbacyclins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Emergency Protection Circuit Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
  • Furan Compounds (AREA)
  • Indole Compounds (AREA)
DK333385A 1984-07-23 1985-07-22 Prostaglandinanaloge, fremgangsmaader til fremstilling heraf samt pharmaceutiske midler med indhold heraf DK333385A (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP59151369A JPS6130554A (ja) 1984-07-23 1984-07-23 プロスタグランジン類似化合物のある特定の立体配置を有する異性体及びそれらを有効成分として含有する治療剤

Publications (2)

Publication Number Publication Date
DK333385D0 DK333385D0 (da) 1985-07-22
DK333385A true DK333385A (da) 1986-01-24

Family

ID=15517042

Family Applications (1)

Application Number Title Priority Date Filing Date
DK333385A DK333385A (da) 1984-07-23 1985-07-22 Prostaglandinanaloge, fremgangsmaader til fremstilling heraf samt pharmaceutiske midler med indhold heraf

Country Status (17)

Country Link
US (2) US4935446A (da)
EP (1) EP0196380B1 (da)
JP (1) JPS6130554A (da)
KR (1) KR860001119A (da)
AT (1) ATE67484T1 (da)
AU (1) AU596947B2 (da)
CA (1) CA1264320A (da)
DE (1) DE3584158D1 (da)
DK (1) DK333385A (da)
ES (3) ES8609232A1 (da)
FI (1) FI852856A7 (da)
GR (1) GR851812B (da)
HU (1) HU199781B (da)
NO (1) NO852916L (da)
PT (1) PT80848B (da)
YU (3) YU45985B (da)
ZA (1) ZA855533B (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2192395B (en) * 1986-07-08 1990-11-14 Kotobuki Seiyaku Co Ltd Carbacyclin derivatives
US5218139A (en) * 1990-12-27 1993-06-08 G. D. Searle & Co. Method for inhibiting IgE production
US5148032A (en) * 1991-06-28 1992-09-15 Siemens Medical Laboratories, Inc. Radiation emitting device with moveable aperture plate
US5235816A (en) * 1991-10-10 1993-08-17 Praxair Technology, Inc. Cryogenic rectification system for producing high purity oxygen
MY144968A (en) 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
AR053710A1 (es) * 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
EP3205644A1 (en) 2005-12-29 2017-08-16 Celtaxsys Inc. Diamine derivatives as inhibitors of leukotriene a4 hydrolase
WO2008046049A1 (en) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-c] pyridine-3-3 ' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
EP2073806B1 (en) 2006-10-12 2012-02-15 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
WO2010045197A1 (en) * 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Spiro-oxindole compounds and their use as therapeutic agents
HRP20150882T1 (hr) * 2008-10-17 2015-09-25 Xenon Pharmaceuticals Inc. Spirooksindolski spojevi i njihova upotreba kao terapijska sredstva
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
PE20170202A1 (es) 2009-10-14 2017-03-24 Xenon Pharmaceuticals Inc Metodos sinteticos para compuestos espiro-oxoindol
US20110086899A1 (en) * 2009-10-14 2011-04-14 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
RU2596488C2 (ru) 2010-02-26 2016-09-10 Ксенон Фармасьютикалз Инк. Фармацевтические композиции спиро-оксиндольного соединения для местного введения и их применение в качестве терапевтических агентов
KR20150002794A (ko) 2012-04-12 2015-01-07 제논 파마슈티칼스 인크. 치료제로서 유용한 스파이로-옥시인돌 화합물을 위한 비대칭적 합성
AU2014240042C1 (en) 2013-03-14 2019-09-05 Celltaxis, Llc Inhibitors of leukotriene A4 hydrolase
AR103636A1 (es) 2015-02-05 2017-05-24 Teva Pharmaceuticals Int Gmbh Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
WO2017218920A1 (en) 2016-06-16 2017-12-21 Teva Pharmaceuticals International Gmbh Asymmetric synthesis of funapide
CA3045887A1 (en) 2016-12-09 2018-06-14 Celtaxsys, Inc. Pendant amines and derivatives as inhibitors of leukotriene a4 hydrolase
US10202362B2 (en) 2016-12-09 2019-02-12 Celtaxsys, Inc. Inhibitors of leukotriene A4 hydrolase
WO2018107158A1 (en) 2016-12-09 2018-06-14 Celtaxsys, Inc. Monamine and monoamine derivatives as inhibitors of leukotriene a4 hydrolase

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087620A (en) * 1975-07-17 1978-05-02 Ono Pharmaceutical Company 15-Cycloalkyl-prostaglandin derivatives
US4180675A (en) * 1975-07-17 1979-12-25 Warner-Lambert Company 15-Cycloalkyl-prostaglandin derivatives
US4178367A (en) * 1977-02-21 1979-12-11 Ono Pharmaceutical Co. Ltd. Prostaglandin I2 analogues
JPS53103464A (en) * 1977-02-21 1978-09-08 Ono Pharmaceut Co Ltd Prostaglandin x analogues and process for their preparation
JPS53127441A (en) * 1977-04-11 1978-11-07 Ono Pharmaceut Co Ltd Prostaglandin-like compounds and their preparation
GB1588196A (en) * 1977-06-14 1981-04-15 Ono Pharmaceutical Co Prostaglandin analogues
JPS6022710B2 (ja) * 1977-09-16 1985-06-03 小野薬品工業株式会社 プロスタグランジン類似化合物
JPS54125653A (en) * 1978-03-18 1979-09-29 Ono Pharmaceut Co Ltd Prostaglandin i2 analog, its preparation, and drug composition comprising it as active constituent
DE2912409A1 (de) * 1978-03-31 1979-10-11 Ono Pharmaceutical Co 6,9-methano-pgi tief 2 -analoge
JPS54130543A (en) * 1978-03-31 1979-10-09 Ono Pharmaceut Co Ltd Prostagladin i2 analog, and its preparation
US4220795A (en) * 1978-08-14 1980-09-02 Miles Laboratories, Inc. Cyclobutyl substituted derivatives of prostaglandin analogs
DE2902809A1 (de) * 1979-01-25 1980-08-07 Hoechst Ag Neue analoga von prostacyclin
DE3006865A1 (de) * 1980-02-23 1981-09-10 Hoechst Ag, 6000 Frankfurt Hetero-imino-prostacycline
JPS58164512A (ja) * 1982-03-25 1983-09-29 Ono Pharmaceut Co Ltd プロスタグランジン類似化合物を有効成分として含有する肝臓疾患治療剤
JPS591463A (ja) * 1982-06-28 1984-01-06 Ono Pharmaceut Co Ltd 新規なプロスタグランジンd類似化合物
JPS5944340A (ja) * 1982-09-08 1984-03-12 Sankyo Co Ltd メタノプロスタサイクリン誘導体の光学活性結晶性アミン塩およびその製法
JPS59163365A (ja) * 1983-03-08 1984-09-14 Ono Pharmaceut Co Ltd プロスタグランジン類似化合物

Also Published As

Publication number Publication date
FI852856L (fi) 1986-01-24
ES545457A0 (es) 1986-09-01
JPS6130554A (ja) 1986-02-12
YU143387A (en) 1988-04-30
YU45985B (sh) 1992-12-21
GR851812B (da) 1985-11-26
CA1264320A (en) 1990-01-09
KR860001119A (ko) 1986-02-22
EP0196380A3 (en) 1987-07-01
US5109021A (en) 1992-04-28
AU4523285A (en) 1986-01-30
FI852856A0 (fi) 1985-07-22
HU199781B (en) 1990-03-28
US4935446A (en) 1990-06-19
AU596947B2 (en) 1990-05-24
EP0196380A2 (en) 1986-10-08
ES8705384A1 (es) 1987-05-01
ES8705385A1 (es) 1987-05-01
ATE67484T1 (de) 1991-10-15
ES552553A0 (es) 1987-05-01
DE3584158D1 (de) 1991-10-24
NO852916L (no) 1986-01-24
ZA855533B (en) 1986-03-26
YU143287A (en) 1988-04-30
PT80848B (pt) 1987-11-30
ES8609232A1 (es) 1986-09-01
YU120185A (en) 1988-04-30
EP0196380B1 (en) 1991-09-18
FI852856A7 (fi) 1986-01-24
PT80848A (en) 1985-08-01
YU46220B (sh) 1993-05-28
ES552554A0 (es) 1987-05-01
YU46219B (sh) 1993-05-28
HUT39157A (en) 1986-08-28
DK333385D0 (da) 1985-07-22

Similar Documents

Publication Publication Date Title
DK333385D0 (da) Prostaglandinanaloge, fremgangsmaader til fremstilling heraf samt pharmaceutiske midler med indhold heraf
IE45390L (en) Anti-caries composition
HUT44171A (en) Process for producing peroral pharmaceutical compositions with acid sensitive active components
PT84249A (en) Process for preparing 5-amino-4-hydroxyvaleric acid derivatives substituted by sulphur-containing groups
EP0165033A3 (en) Conformationally restricted thymopentin-like compounds
HUT43494A (en) Process for producing pharmaceutical composition containing interferone-alpha
ES2000368A6 (es) Un procedimiento para preparar di-t-butilfenoles sustituidos
CA2008183A1 (en) Liquid pharmaceutical composition for piperidinoalkanol derivatives
CA1268171C (en) METHOD OF PREPARATION IN A SINGLE CONTAINER OF 7.beta.-AMINO- AND 7.beta.-ACYLAMINO-3-METHYL-SUBSTITUTE-3-CEPHEM-4-CARBOXYLIC ACID DERIVATIVES AND METHOD OF DEOXYGENATION OF ACID 1-OXIDE DERIVATIVES 7.beta.-ACYLAMINO-3-CEPHEM-4-CARBOXYLIC
JPS6490181A (en) Disubstituted cyclic ether carboxylic acids, derivatives, composition and use
DE3068250D1 (en) 3-hydroxymethyldibenzo(b,f)thiepins and dibenzo(b,f)thiepin-3-carboxaldehydes as prostaglandin antagonists, process for their preparation and pharmaceutical compositions
ES477656A1 (es) Procedimiento para preparar acidos azulminicos modificados.
IE44350L (en) 6ß,7Ó-DISUBSTITUTED-STEROID-17-SPIRO LACTONES AND CONGENERS
IE43708L (en) D-homosteroid carboxylic acids
ES8504160A1 (es) Procedimiento para la preparacion de derivados de propan-2-ol
CA1034521A (en) PROCESS FOR THE PREPARATION OF 17-ACYL ESTERS OF 17.alpha.,21-DIHYDROXYSTEROIDS OF THE PREGNANE SERIES
JPS545931A (en) Prearation of n,n-dialkyltoluamide
JPS52106857A (en) Preparation of 1,3-disubstituted-2-azetidinones
GR3021467T3 (en) New peptide derivates active in the process of cell adhesion, a method to prepare them end pharmaceutical compositions containing them.
JPS53149991A (en) Preparation of 3-heterothiomethyl-1-oxadethia-3-cephem-4-carboxylic acid
JPS53103412A (en) Preparation of farnesyl acetic acid or its ester
JPS5293787A (en) Novel process for preparation of cephem derivatives
JPS5353684A (en) Preparation of dibenzazepin derivatives
JPS5253854A (en) Preparing optical active pyprolidine ethanols
JPS5285119A (en) Preparation of tartaric acid